
Journal of the Neurological Sciences Volume 455, Supplement, December 2023, 122574



PV1396 / #2130

Clinical course of Parkinson[StQuote]s disease in patients with COVID-19

Author links open overlay panelJavlon Salimjonov, Rustambek Matmurodov, Bekzod Muminov Show more Add to Mendeley Share Cite

https://doi.org/10.1016/j.jns.2023.122574Get rights and content

Section snippets

Background and aims

The SARS-CoV-2 virus can also directly affect the nigrostriatal system, and this is a special neurotropic property of the virus. To study the clinical course of PD in patients with COVID-19.

Methods

66 patients with PD (33 men and 33 women) were enrolled for the study. The average age of the patients was 61-76 years, with an average of 78.5 ± 5.5 years. The average duration of the disease is 4.6 ± 3.4 years. The Unified Parkinson's Disease Rating Scale was examined. Disease stages were evaluated according to Xen and Yar.

Results

The clinical forms of the disease were determined in 22 patients with akinetic-rigid form, in 26 patients tremor form and in 18 patients mixed form. Stage 1 was defined in 24 patients, stage 2 in 27 patients, and stage 3 in 15 patients. UPDRS -28.5 ± 9.8 points. When comparing the clinical forms of the disease after the transfer of Covid-19, the akinetic-rigid form was observed in 14 patients, the tremor form was observed in 29 patients, and the mixed form was observed in 23 patients. Stages of

Conclusions

Covid-19 infection strongly affects the clinical course of PD, exacerbating both movement-related motor and non-motor disorders. Accelerates the transformation of the disease to another severe clinical form, stages of the disease.

References (0)

Cited by (0)

View full text